ReviewBMC neurology2026
Neuronal intranuclear inclusion disease caused by NOTCH2NLC gene expansion: a case report and literature review.
Review in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuronal intranuclear inclusion disease (NIID) is an extremely rare, slowly progressive neurodegenerative disorder characterized by episodic neurological and psychiatric symptoms. Diagnosis is challenging due to non-specific presentations, often leading to misdiagnosis. Key diagnostic features include characteristic diffusion-weighted imaging (DWI) abnormalities, eosinophilic intranuclear inclusions on skin biopsy, and GGC repeat expansions in the NOTCH2NLC gene. CASE PRESENTATION: A 56-year-old woman presented with acute onset confusion, disorientation, personality changes (inappropriate verbal outbursts), and aimless wandering. Symptoms were episodic and fluctuating. Past history included a right hemispheric ischemic stroke with residual hemiparesis, type 2 diabetes mellitus, and organophosphate poisoning. Initial admission diagnosis was "metabolic encephalopathy." Serial brain MRI+DWI over 3 years consistently showed symmetric hyperintensity on DWI along the corticomedullary junction in bilateral fronto-parieto-temporal white matter, semioval centers, and corpus callosum (ribbon sign). Cerebrospinal fluid analysis showed normal protein levels and lymphocytic pleocytosis (118.80 cells/μL). Episodic cognitive fluctuations persisted despite standard medical management. Given the characteristic DWI findings and clinical course, NIID was suspected. Genetic testing confirmed a pathogenic heterozygous NOTCH2NLC GGC repeat expansion (n=16/101 repeats). Skin biopsy and EMG were declined. Family history revealed a daughter with suspected cognitive issues. A diagnosis of NIID was confirmed.
conclusionsThis report details the first genetically confirmed case of NIID in our region, presenting primarily with episodic psychiatric symptoms. It highlights the diagnostic challenge and the critical role of recognizing the characteristic DWI ribbon sign and performing genetic testing for NOTCH2NLC expansions, especially in cases with unexplained episodic neuropsychiatric decline. Increased awareness and accessibility of genetic testing will likely lead to more frequent diagnosis of NIID in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.